BCMA CAR-T cells in multiple myeloma–ready for take-off?
L Scheller, E Tebuka, PF Rambau, H Einsele… - Leukemia & …, 2024 - Taylor & Francis
Although the approval of new drugs has improved the clinical outcome of multiple myeloma
(MM), it was widely regarded as incurable over the past decades. However, recent …
(MM), it was widely regarded as incurable over the past decades. However, recent …
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Y Pang, N Ghosh - Frontiers in Oncology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
Challenges in Global Access to CAR-T cells: an Asian Perspective
The use of cell therapy for clinical applications has seen a dramatic increase in recent years,
primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell …
primarily in oncology, especially with the use of chimeric antigen receptor (CAR) T-cell …
How Do We Manage Chronic Lymphocytic Leukemia in India
P Karunakaran, N Jain, DP Lad - Current Hematologic Malignancy Reports, 2024 - Springer
Abstract Purpose of Review Chronic lymphocytic leukemia was an ignored leukemia in India
until a decade back, given its low prevalence and absence of novel drugs to treat it …
until a decade back, given its low prevalence and absence of novel drugs to treat it …
Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond
P Khodke, BV Kumbhar - Advances in Protein Chemistry and Structural …, 2024 - Elsevier
Abstract Chimeric Antigen Receptor (CAR) T cell therapy is a type of adoptive
immunotherapy that offers a promising avenue for enhancing cancer treatment since …
immunotherapy that offers a promising avenue for enhancing cancer treatment since …
Challenges in Administering Salvage Therapy and Outcomes of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A LMIC Real-World Study
Standard therapy for patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR
DLBCL) involves salvage chemotherapy followed by autologous hematopoietic stem cell …
DLBCL) involves salvage chemotherapy followed by autologous hematopoietic stem cell …
Unmet Need and Potential Barriers for Chimeric Antigen Receptor T Cell Therapy in India
journal homepage: www. astctjournal. org annually, who would be eligible for CAR-T (Figure
1), highlighting a large currently unmet need in India. We asked questions regarding …
1), highlighting a large currently unmet need in India. We asked questions regarding …